Skip to main content
. 2020 Sep 5;19:47–56. doi: 10.1016/j.omto.2020.09.001

Figure 2.

Figure 2

Validation of the 70-Gene Signature in Tumor Stage

(A) Patients were separated according to early- and advanced-stage cancer. (B–E) The 70-gene signature was applied to cancer patients of all stages (B), early stage (C), advanced stage (D), and advanced stage after 9 months (E). Each group was classified by the 70-gene signature into low and high risk, and evaluated by Kaplan-Meier analysis. The p values were computed by the log rank test.